Gene therapy for cystic fibrosis

Bibliography

• SHEFF B: Herpes simplex virus. Nursing (2000) 30:30–42.
   PubMedGoogle Scholar
• FITZPATRICK CA: Herpes simplex infection. J. Am. Acad. Nurse Pract. (1999) 11:539–548.
   PubMedGoogle Scholar
• RAMANATHAN J, RAMMOUNI M, BARAN J, KHATIB R: Herpes simplex virus esophagitis in the immunocom-petent host: an overview. Am. J Gastroenterol (2000) 95:2171–2176.
   PubMed Web of Science ®Google Scholar
• JONES CA, TAYLOR TJ, KNIPE DM: Biological properties of herpes simplex virus 2 replication-defective mutant strains in a murine nasal infection model. Virology (2000) 278:137–150.
   PubMed Web of Science ®Google Scholar
• SLOMKA MJ: Current diagnostic techniques in genital herpes: their role in controlling the epidemic. Clin. Lab. (2000) 46:591–607.
   PubMedGoogle Scholar
• SNOECK R, ANDREI G, DE CLERCQ E: Novel agents for the therapy of varicella zoster virus infections. Exp. Opin. Invest. Drugs (2000) 9:1743–1751.
   PubMed Web of Science ®Google Scholar
• MADISON LK: Shingles update: common questions in caring for a patient with shingles. Orthop. Nurs. (2000) 19:59–62.
   PubMedGoogle Scholar
• DELECLUSE HJ, HAMMERSCHMIDT W: The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy. Mol. Pathol. (2000) 53:270–279.
   PubMedGoogle Scholar
• BUISSON M, CHAVANET P: Infectious mononucleosis. Epidemiology, diagnosis, development. Rev. Prat. (2000) 50:1253–1256.
   PubMedGoogle Scholar
• EMERY VC, COPE AV, BOWEN EF, GOR D, GRIFFITHS PD: The dynamics of human cytomegalovirus replication in vivo. J. Exp. Med. (1999) 190:177–182.
   PubMed Web of Science ®Google Scholar
• KNOX KK, BREWER JH, HENRY JM, HARRINGTON DJ, CARRIGAN DR: Human herpes virus 6 and multiple sclerosis: systematic active infections in patients with early disease. Clin. Infect. Dis. (2000) 31:894–903.
   PubMed Web of Science ®Google Scholar
• BLACK JB, PELLET PE: Human herpes virus 7. Rev. Med. Virol. (1999) 9:245–262.
   PubMed Web of Science ®Google Scholar
• GREENBLATT RM: Human herpes virus 8 infections. Curr. Infect. Dis. Rep. (1999) 1:279–288.
   PubMedGoogle Scholar
• KATANO H, SATE T: Human herpes virus 8: virology, epidemiology and related diseases. Jpn. J Infect. Dis. (2000) 53:137–155.
   PubMed Web of Science ®Google Scholar
• ROTOLA A, CASELLI E, CASSAI E, TOLA MR, GRANIERI E, LUCA DD: Novel human herpesviruses and multiple sclerosis. J. Neurovirol. (2000) 2 (Suppl.):S88–91.
   Google Scholar
• FIELD AK: Human cytomegalovirus: challenges opportunities and new drug development. Antiviral Chem. Chemother. (1999) 10:219–232.
   PubMed Web of Science ®Google Scholar
• BALDANTI F, SARASINI A, FURIONE M et al.: Coinfection of the immunocompromised but not the immunocom-petent host by multiple human cytomegalovirus strains. Arch. Virol. (1998) 143:1701–1709.
   PubMed Web of Science ®Google Scholar
• TRINCADO DE, SCOTT GM, WHITE PA, HUNT C, RASMUSSEN L, RAWLINSON WD: Human cytomega-lovirus strains associated with congenital and perinatal infections. J Med. Vim]. (2000) 61:481–487.
   PubMed Web of Science ®Google Scholar
• CASTRO A, MARTINEZ A: Novel agents for the treatmentof human cytomegalovirus infection. Exp. Opin. Ther. Patents (2000) 10:167–177.
   Web of Science ®Google Scholar
• MARTINEZ A, CASTRO A, GIL C, PEREZ C: Recent strate-gies in the development of new human cytomega-lovirus inhibitors. Med. Res. Rev. (2001):In press.
   Google Scholar
• XIONG X, SMITH JL, CHEN MS: Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. (1997) 41:594–599
   PubMed Web of Science ®Google Scholar
• ERICE A: Resistance of human cytomegalovirus to antiviral drugs. Clin. Mkrobiol. Rev. (1999) 12:286–297.
   PubMed Web of Science ®Google Scholar
• NEUZIL KM: Influenza: new insights into an old disease. Curr. Infect. Dis. Rep. (2000) 2:224–230.
   PubMedGoogle Scholar
• OTTOLINI MG: Current and future use of vaccines for viral and bacterial respiratory tract infections. Curr. Infect. Dis. Rep. (2000) 2:121–129.
   PubMedGoogle Scholar
• KING JC: Influenza vaccines. Pedriatr. Ann. (2000) 29:692–697.
   PubMed Web of Science ®Google Scholar
• CASERTA MT, HALL CB: Antiviral agents for influenza. Pediatr. Ann. (2000) 29 :704–711.
   PubMed Web of Science ®Google Scholar
• SUMMERFIELD JA: Virus hepatitis update. J. R. Coll. Physicians Lond. (2000) 34:381–385.
   PubMedGoogle Scholar
• HAN SH, SAAB S, MARTIN P: Acute viral hepatitis. Curr. Treat. Options Gastroenterol. (2000) 3:481–486.
   PubMedGoogle Scholar
• ALEXANDER G, WALSH K: Chronic viral hepatitis. Int. J. Pract. (2000) 54:450–456.
   PubMed Web of Science ®Google Scholar
• VALICENTI MR, VENKATARAMAN G, SHNEIDER B: Clinical quiz. Hepatitis A. J. Pediatr. Gastroenterol. Nutr. (2000) 31:457–463.
   PubMed Web of Science ®Google Scholar
• STRASSER SI, MCCAUGHAN GW: Therapies for chronic hepatitis B: emerging roles for nucleoside analogues. Aust. NZ J. Med. (2000) 30:556–558.
   PubMedGoogle Scholar
• SCHALM SW, WOLTERS LM, VAN NUNEN AB, NIESTERSHG, DE MAN RA: New nucleosides analogues for chronic hepatitis B. Acta Gastroenetrol. Belg. (2000) 63 :191–193 .
   PubMed Web of Science ®Google Scholar
• SCHAFER DF, SORRELL MF: Con quering h ep atitis C, step by step. N Engl. J. Med. (2000) 343:1723–1724.
   PubMedGoogle Scholar
• CHOO QL, KUO G, WEINER AJ, OVERBY LR, BRADLEY DW, HOUGHTON M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 244:359–362.
   PubMed Web of Science ®Google Scholar
• LEEVY CB, ZIERER KG, LEEVY CM: Viral hepatitis C. J.Assoc. Acad. minor Phys. (1998) 9:59–64.
   PubMedGoogle Scholar
• LECHMAN M, LIANG TJ: Vaccine development for hepatitis C. Semin. Liver Dis. (2000) 20:211–226.
   PubMed Web of Science ®Google Scholar
• DYMOCK BW, JONES PS, WILSON FX: Novel approaches to the treatment of hepatitis C virus infection. Antivir. Chem. Chemother. (2000) 11:79–96.
   PubMed Web of Science ®Google Scholar
• REDING MT: Recent developments in hepatitis C antiviral research 1999-2000. Exp. Opin. Ther. Patents (2000) 10:1201–1220.
   Web of Science ®Google Scholar
• BURAK KW, LEE SS: Treatment options in patients with chronic hepatitis C. Can. J. Public Health (2000) 91 (Suppl. 1):S22–26.
   Google Scholar
• LUKASHOV W, DE RONDE A, DE JONG JJ, GOUDSMIT J: Epidemiology of HIV-1 and emerging problems. Int. J. Antimicrob. Agents (2000) 16:463–466.
   PubMed Web of Science ®Google Scholar
• PADIERNA-OLIVOS L, MORENO-ALTAMIRANO MM, SANCHEZ-COLON S, MASSO-ROJAS F, SANCHEZ-GARCIA FJ: Connectivity and HIV-1 infection: role of CD4+ T-cell counts and HIV-1 RNA copy number. Scand. Immunol. (2000) 5 2 :618–627.
   Google Scholar
• IKEDA M, YOSHIDA S: H1V-1 and scrub-typhus. Lancet (2000) 356:1851.
   Google Scholar
• DE CLERCQ E: Novel compounds in preclinical/early clinical development for the treatment of HIV infections. Rev. Med. Virol. (2000) 10:255–277.
   PubMed Web of Science ®Google Scholar
• BLAIR WS, LIN PF, MEANWELL NA, WALLACE OB: entry, an expanding portal for the drug discovery. Drug Discov. Today (2000) 5:183–194.
   PubMed Web of Science ®Google Scholar
• FACKLER OT, PETERLIN BM: Endocytic entry of H1V-1 Curr. Biol. (2000) 24:1005–1008.
   Google Scholar
• JOLY V, YENI P: Non-nucleoside reverse transcriptase inhibitors. Ann. Med. Interne (Paris) (2000) 151:260–267.
   PubMedGoogle Scholar
• KAUFMANN GR, COOPER DA: Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options. Curr. Opin. Microbiol. (2000) 3:508–514.
   PubMed Web of Science ®Google Scholar
• MORI K, YASUTOMI Y, SAWADA S et al: Suppression of acute viremia by short term postexposure prophy-laxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection. J Virol. (2000) 74:5747–5753.
   PubMed Web of Science ®Google Scholar
• PANI A, MARONGIU ME: Anti-H1V-1 integrase drugs: now far from the shelf? Curr. Pharm. Des. (2000) 6:569–584.
   Google Scholar
• NEAMATI N, MARCHAND C, POMMIER Y: HIV-1 integraseinhibitors: past, present and future. Adv. Pharmacol (2000) 49:147–165.
   PubMedGoogle Scholar
• POMMIER Y, MARCHAND C, NEAMATI N: Retroviral integrase inhibitors year 2000: update and perspec-tives. Antiviral Res. (2000) 47:139–148.
   PubMed Web of Science ®Google Scholar
• WEI X, GOTTE M, WAINBERG MA: Human immunodefi-ciency virus type-1 reverse transcription can be inhibited in vitro by oligonucleotides that target both © Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(2) natural and synthetic tRNA primers. Nucleic Acids Res. (2000) 28:3065–3074.
   Google Scholar
• CALZADO MA, MACHO A, LUCENA C, MUNOZ E: Hydroxyurea inhibits the transactivation of the HIV-long-terminal repeat (LTR) promoter. Clin. Exp. Immunol. (2000) 12 0 :317–323.
   Google Scholar
• ROBINSON LH, MYERS RE, SNOWDEN BW, TISDALE M,BLAIR ED: HIV Type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. AIDS Res. Hum. Retroviruses (2000) 16:1149–1156.
   PubMed Web of Science ®Google Scholar
• DARBYSHIRE J: Therapeutic interventions in HIVinfection: a critical view. Trop. Med. Int. Health (2000) 5:A26–31.
   Web of Science ®Google Scholar
• CONDRA JH, PETROPOULOS CJ, ZIERMANN R, SCHLEIF WA, SHIVAPRAKASH M, EMINI EA: Drug resistance and predicted virologic responses to human immunodefi-ciency virus Type 1 protease inhibitor therapy. J Infect. Dis. (2000) 182:758–765.
   PubMed Web of Science ®Google Scholar
• NATHANSON N, MATHIESON BJ: Biological considera-tions in the development of a human immunodefi-ciency virus vaccine. J Infect. Dis. (2000) 182:579–589.
   PubMed Web of Science ®Google Scholar
• HEENEY JL, HAHN BH: Vaccines and immunology: elucidating to HIV-1 and current prospects for AIDS vaccine development. AIDS (2000) 14:S125–127.
   Web of Science ®Google Scholar
• RESINO S, BELLON JM, SANCHEZ-RAMON S, GURBINDO D, MUNOZ-FERNANDEZ MA: Clinical relevance of cytokine production in HIV-1 infection in children on antiretroviral therapy. Scand. J. Immunol. (2000) 52:634–640.
   PubMed Web of Science ®Google Scholar
• CABEZAS E, WANG M, PARREN PW, STANFIELD RL, SATTERTHWAIT AC: A structure-based approach to a synthetic vaccine for HIV-1. Biochemistry (2000) 28:14377–14391.
   Google Scholar
• BRENNER B, WAINBERG MA, SALOMON H et al.: Resistance to antiretroviral drugs in patients with primary inv-1 infection. Int. J Antimicrob. Agents (2000) 16:429–434.
   PubMed Web of Science ®Google Scholar
• HANNA GJ, D'AQUILA RT: An tir etr o vir al drug r esistan ce in Hill-1 Curr. Infect. Dis. Rep. (2000) 1:289–297.
   Google Scholar
• OMRANI AS, PILLAY D: Multi-drug resistant H1V-1 J. Infect. (2000) 41:5–11.
   Web of Science ®Google Scholar